MarginsXMarginsX
Home › Markets › Health Care › BOLT

Bolt Biotherapeutics Inc. (BOLT)

BOLT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.80
-4.61% on the day
Market cap
$15.1M
Nano cap
Revenue · 2025
$7.7M
+0.1% on 2024
Net income · 2025
-$33.4M
-433.7% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1641281/000119312526104121/0001193125-26-104121-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerBOLT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2021
SEC CIK0001641281
SEC industry codePharmaceutical Preparations
Incorporated inDE

Financials · 2025

LineValue
Revenue$7.7M
Net income-$33.4M
Operating income-$36.1M
Net margin-433.7%
Operating margin-469.3%
Revenue growth+0.1%
Cash$11.7M
Total assets$56.7M
P/E (computed)Net income was not positive
P/S (computed)2.0×

Warning signs

Cash runway
6.7 months
$13.8M cash at September 30, 2026
Share count, 1 year
+35.8%
2025-11-05 to 2026-11-06 · +37.4% over 3 years
Going-concern doubt
Yes
10-Q filed November 13, 2026
Insider net buying, 12 months
-$123K
Through September 30, 2026
SignFindingSource
Going concernStates substantial doubt about continuing as a going concern.
"The Company has concluded that substantial doubt exists about its ability to continue as a going concern."
10-Q 2026-11-13
Cash and burn$13.8M cash; operating cash flow -$6.2M a quarter.Report 2026-09-30
Shares outstanding2,607,490 (2026-11-06); 1,919,441 a year earlier; 37,965,870 three years earlier. 3y figure adjusted for split (1-for-20 overall).Cover page 2026-11-06
Reverse splits, 3 years1; latest 1-for-20 on 2025-06-09Source 2025-06-09
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-20
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $5K, sold $128K on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$0-$4.4M-$3.1M$13.8MNo debt tags$2.5M10-Q 2026-11-13
Q2 2026
2026-06-30
$5K-$7.5M-$6.5M$12.9MNo debt tags$4.7M10-Q 2026-08-11
Q1 2026
2026-03-31
$26K-$7.7M-$8.0M$11.6MNo debt tags$6.5M10-Q 2026-05-12
Q4 2025
2025-12-31
$2.5M-$6.6M-$7.2M$11.7MNo debt tags$7.7M10-K 2026-03-12
Q3 2025
2025-09-30
$2.2M-$7.1M-$9.7M$17.8MNo debt tags$5.2M10-Q 2026-11-13
Q2 2025
2025-06-30
$1.8M-$8.6M-$9.6M$9.6MNo debt tags$4.2M10-Q 2026-08-11
Q1 2025
2025-03-31
$1.2M-$11.0M-$13.4M$8.4MNo debt tags$3.6M10-Q 2026-05-12
Q4 2024
2024-12-31
$0-$15.9M-$14.4M$7.2MNo debt tags$7.7M10-K 2026-03-12

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B52022-04-07
Latest annual report10-K2026-03-12
Latest quarterly / interim10-Q2026-11-13
Latest current report8-K2026-11-12
Latest proxyDEFA14A2026-04-28

Source: SEC EDGAR submissions feed, 300 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-7.0%
1 month+41.9%
3 months+89.4%
Year to date+11.2%
1 year+29.4%
From 52-week high-14.2%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
AKTXAkari Therapeutics plc ADS$6.51-4.26%$15.1M
PBMPsyence Biomedical Ltd. Common Shares$2.83-11.56%$15.0M
CNTXContext Therapeutics Inc.$0.1659-8.24%$15.2M
ACTUActuate Therapeutics Inc.$0.2680-7.59%$14.7M
TVRDTvardi Therapeutics Inc.$1.10-6.78%$14.7M
CTXRCitius Pharmaceuticals Inc.$0.5276-1.40%$14.5M
NCELNewcelX Ltd.$2.75+5.36%$15.9M
MCRBSeres Therapeutics Inc.$1.41+0.71%$14.4M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier